Background: Photodynamic therapy (PDT) using topical δ-aminolevulinic acid (ALA) has been used for nonmelanoma skin cancers, including malignant cutaneous T-cell lymphomas. Moreover, PDT has been tried for benign inflammatory or infectious skin lesions. Objective: To evaluate the effects of ALA-PDT on skin lesions of lymphadenosis benigna cutis (LABC). Patients and Methods: Two 16-year-old females with solitary and infiltrated nodules were treated 5 times with topical ALA-PDT. Results: Both patients responded well and showed dramatic clinical and histopathological improvement without visible scars. Conclusion: The results confirm that topical ALA-PDT is an effective and safe modality for the treatment of LABC, and that such treatment may be cosmetically beneficial.

Keywords:
Photodynamic therapy, δ-Aminolevulinic acid, Lymphadenosis benigna cutis, Benign lymphoid hyperplasia
1.
Cairnduff F, Stringer MR, Hudson EJ, Ash DV, Brown SB: Superficial photodynamic therapy with topical δ-aminolaevulinic acid for superficial primary and secondary skin cancer. Br J Cancer 1994;69:605–608.
2.
Svanberg K, Andersson T, Killander D, Wang I, Stenram U, Andersson-Engels S, Berg R, Johansson J, Svanberg S: Photodynamic therapy of non-melanoma malignant tumours of skin using topical δ-amino levulinic acid sensitization and laser irradiation. Br J Dermatol1994;130:743–751.
3.
Wolf P, Fink-Puches R, Cerroni L, Kerl H: Photodynamic therapy for mycosis fungoides after topical photosensitization with δ-aminolevulinic acid. J Am Acad Dermatol 1994;31:678–680.
4.
Ammann R, Hunziker T: Photodynamic therapy for mycosis fungoides after topical photosensitization with δ-aminolevulinic acid. J Am Acad Dermatol1995;33:541.
5.
Markham T, Sheahan K, Collins P: Topical δ-aminolaevulinic acid photodynamic therapy for tumour-stage mycosis fungoides. Br J Dermatol2001;144:1262–1263.
6.
Dougherty TJ, Kaufman JE, Goldfarb A, Weishaupt KR, Boyle D, Mittleman A: Photoradiation therapy for the treatment of malignant tumors. Cancer Res 1978;38:2628–2635.
7.
Orenstein A, Haik J, Tamir J, Winkler E, Trau H, Malik Z, Kostenich G: Photodynamic therapy of cutaneous lymphoma using δ-aminolevulinic acid topical application. Dermatol Surg2000;26:765–770.
8.
Umegaki N, Moritsugu R, Katoh S, Harada K, Nakano H, Tamai K, Hanada K, Tanaka M: Photodynamic therapy may be useful in debulking cutaneous lymphoma prior to radiotherapy. Clin Exp Dermatol 2004;29:42–45.
9.
MacKie R: Cutaneous lymphocytic infiltrates and pseudolymphomas; in Rook AJ, Wilkinson DS, Ebling FJ (eds): Textbook of Dermatology. Oxford, Blackwell, 1992, pp 2101–2105.
10.
Kuflik AS, Schwartz RA: Lymphocytoma cutis: A series of patient successfully treated with cryosurgery. J Am Acad Dermatol1992;26:449–452.
11.
Boehncke WH, Sterry W, Kaufmann R: Treatment of psoriasis by topical photodynamic therapy with polychromatic light. Lancet 1994;343:801.
12.
Boehncke WH, Elshorst-Schmidt T, Kaufmann R: Systemic photodynamic therapy is a safe and effective treatment for psoriasis. Arch Dermatol 2000;136:271–272.
13.
Itoh Y, Ninomiya Y, Tajima S, Ishibashi A: Photodynamic therapy of acne vulgaris with topical delta-aminolaevulinic acid and incoherent light in Japanese patients. Br J Dermatol 2001;144:575–579.
14.
Ammann R, Hunziker T, Braathen LR: Topical photodynamic therapy in verrucae: A pilot study. Dermatology 1995;191:346–347.
15.
Stender IM, Wulf HC: Treatment of recalcitrant verrucae by photodynamic therapy with topical application of δ-aminolaevulinic acid. Clin Exp Dermatol 1996;21:390.
16.
Mizuki D, Kaneko T, Hanada K: Successful treatment of topical photodynamic therapy using δ-aminolevulinic acid for plane warts. Br J Dermatol 2003;149:1087–1088.
17.
Malik Z, Ehrenberg B, Faraggi A: Inactivation of erythrocytic, lymphocytic and myelocytic leukemic cells by photoexcitation of endogenous porphyrins. J Photochem Photobiol B 1989;4:195–205.
18.
Strauss RM, Ogden S, Sheehan-Dare RA, Goulden V: Leg ulceration after aminolaevulinic acid photodynamic therapy in a patient with peripheral vascular disease. Dermatology 2003;207:85.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.